Rebecca Brückmann on Nostr: This is the problem, right here. Not "off-label" prescriptions, not fat people, not ...
This is the problem, right here. Not "off-label" prescriptions, not fat people, not diabetics. This right here. "Novo’s chief executive recently told CNN that it could take “quite some years” before it can fully meet the demand for Wegovy. In the meantime, it has sued nearly a dozen clinics and pharmacies that market or dispense alternative versions, accusing some of infringing its trademarks":
https://www.washingtonpost.com/business/2023/09/19/ozempic-semaglutide-compounding-pharmacies/Published at
2023-09-24 18:00:52Event JSON
{
"id": "72833d8eb3db8edcb84e21693db8e8a98eca3281435b21595cd774d4814daa3c",
"pubkey": "b24624377a610cfdb2a6be3f52b6cbe27f1ba376447741b822a020b072b8b60a",
"created_at": 1695578452,
"kind": 1,
"tags": [
[
"proxy",
"https://historians.social/users/historleans/statuses/111121429448163896",
"activitypub"
]
],
"content": "This is the problem, right here. Not \"off-label\" prescriptions, not fat people, not diabetics. This right here. \"Novo’s chief executive recently told CNN that it could take “quite some years” before it can fully meet the demand for Wegovy. In the meantime, it has sued nearly a dozen clinics and pharmacies that market or dispense alternative versions, accusing some of infringing its trademarks\": https://www.washingtonpost.com/business/2023/09/19/ozempic-semaglutide-compounding-pharmacies/",
"sig": "cbe0872cd81e5767dfb4f953f4c9f0d8e3021105e0f687929bba01eb07cf61e72fed0c763ee13bdda4e704daed73bcccd304934aed7c752fd3b5891f9c3ed900"
}
